The European Medicines Agency (EMA) has admitted that the planned exit of the U.K. from the European Union (EU) may cause significant disruption to its activities in 2017.
To what degree Brexit will affect the agency is uncertain and will depend on the future relationship between the EU and the U.K., but the EMA warns Brexit could have a major impact on its operations and business plans.
EMA, which is currently conducting a review of gadolinium contrast agents, is based in London, but is almost certain to relocate after Brexit.
In spite of Brexit, the EMA has stated it has finalized a budget of 322 million euros for 2017, which represents an increase of 4.4% compared with 2016's budget. The funds will help cover programs for antimicrobial resistance, access to both human and veterinary medicines, enhanced regulatory capacity and capability, and the agency's commitment to transparency.
